IDEAS home Printed from https://ideas.repec.org/a/spr/hecrev/v13y2023i1d10.1186_s13561-023-00459-2.html
   My bibliography  Save this article

Economic burden of chronic migraine in OECD countries: a systematic review

Author

Listed:
  • Alyaa Eltrafi

    (University of Birmingham)

  • Sunil Shrestha

    (Monash University Malaysia)

  • Ali Ahmed

    (Monash University Malaysia
    Riphah International University)

  • Hema Mistry

    (University of Warwick)

  • Vibhu Paudyal

    (University of Birmingham)

  • Saval Khanal

    (University of East Anglia)

Abstract

Background Chronic migraine (CM) is a significant neurological condition affecting a substantial portion of the global population. The economic burden of CM includes both direct healthcare costs and indirect costs resulting from productivity losses and intangible impacts on patients’ quality of life. However, there is limited research that comprehensively evaluates all cost components associated with CM, highlighting the need for a systematic review. Methods We conducted a systematic literature search in databases including MEDLINE, Embase, and CINAHL to identify studies estimating the cost of illness of chronic migraines. The search was restricted to English language articles published from inception to October 2021, and only findings from Organisation for Economic Co-operation and Development (OECD) countries were included. Methodology features and key findings were extracted from the studies, and reported costs were converted to GBP for cross-country comparisons. Results Thirteen cost-of-illness studies on CM from various OECD countries were included in this review. The studies demonstrated substantial variations in monetary estimates, but consistently highlighted the considerable economic burden of CM. Direct costs, particularly hospitalisation and medication expenses, were identified as the highest contributors. However, indirect costs, such as productivity losses due to absenteeism and presenteeism, were often underexplored in the reviewed studies. Additionally, intangible costs related to emotional and social impacts on patients were largely overlooked. Conclusion Chronic migraine imposes a significant economic burden on individuals, healthcare systems, and society. Policymakers and healthcare stakeholders should consider both direct and indirect cost components, as well as intangible costs, in developing targeted strategies for effective CM management and resource allocation. Further research focusing on comprehensive cost assessments and sensitivity analyses is needed to enhance the understanding of CM’s economic implications and inform evidence-based healthcare policy decisions. Addressing these research gaps can alleviate the economic burden of CM and improve patient outcomes.

Suggested Citation

  • Alyaa Eltrafi & Sunil Shrestha & Ali Ahmed & Hema Mistry & Vibhu Paudyal & Saval Khanal, 2023. "Economic burden of chronic migraine in OECD countries: a systematic review," Health Economics Review, Springer, vol. 13(1), pages 1-10, December.
  • Handle: RePEc:spr:hecrev:v:13:y:2023:i:1:d:10.1186_s13561-023-00459-2
    DOI: 10.1186/s13561-023-00459-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1186/s13561-023-00459-2
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1186/s13561-023-00459-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Tarricone, Rosanna, 2006. "Cost-of-illness analysis: What room in health economics?," Health Policy, Elsevier, vol. 77(1), pages 51-63, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Joanna M Charles & Deirdre M Harrington & Melanie J Davies & Charlotte L Edwardson & Trish Gorely & Danielle H Bodicoat & Kamlesh Khunti & Lauren B Sherar & Thomas Yates & Rhiannon Tudor Edwards, 2019. "Micro-costing and a cost-consequence analysis of the ‘Girls Active’ programme: A cluster randomised controlled trial," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-17, August.
    2. Chien-Yuan Sher & Ho Ting Wong & Yu-Chun Lin, 2020. "The Impact of Dengue on Economic Growth: The Case of Southern Taiwan," IJERPH, MDPI, vol. 17(3), pages 1-12, January.
    3. Hanna Gyllensten & Michael Wiberg & Kristina Alexanderson & Anders Norlund & Emilie Friberg & Jan Hillert & Olivia Ernstsson & Petter Tinghög, 2018. "Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(3), pages 435-446, April.
    4. Karine Chevreul & Coralie Gandré & Karen Berg Brigham & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schiep, 2016. "Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 43-52, April.
    5. Jamison Pike & Scott D. Grosse, 2018. "Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 765-778, December.
    6. Hazo, Jean-Baptiste & Gandré, Coralie & Leboyer, Marion & Obradors-Tarragó, Carla & Belli, Stefano & McDaid, David & Park, A-La & Maliandi, Maria Victoria & Wahlbeck, Kristian & Wykes, Til & van Os, J, 2017. "National funding for mental health research in Finland, France, Spain and the United Kingdom," LSE Research Online Documents on Economics 82339, London School of Economics and Political Science, LSE Library.
    7. Susanne Mayer & Jonah Spickschen & K Viktoria Stein & Richard Crevenna & Thomas E Dorner & Judit Simon, 2019. "The societal costs of chronic pain and its determinants: The case of Austria," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-18, March.
    8. Lan Gao & Hao Hu & Fei-Li Zhao & Shu-Chuen Li, 2016. "Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-17, January.
    9. Bugge, Christoffer & Sæther, Erik Magnus & Brustugun, Odd Terje & Kristiansen, Ivar Sønbø, 2021. "Societal cost of cancer in Norway –Results of taking a broader cost perspective," Health Policy, Elsevier, vol. 125(8), pages 1100-1107.
    10. Karine Chevreul & Morgane Michel & Karen Berg Brigham & Julio López-Bastida & Renata Linertová & Juan Oliva-Moreno & Pedro Serrano-Aguilar & Manuel Posada-de-la-Paz & Domenica Taruscio & Arrigo Schiep, 2016. "Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(1), pages 7-18, April.
    11. Paul Hanly & Rebecca Maguire & Frances Drummond & Linda Sharp, 2019. "Variation in the methodological approach to productivity cost valuation: the case of prostate cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(9), pages 1399-1408, December.
    12. Miley, Frances & Read, Andrew, 2021. "Soldiers don't go mad: Shell shock and accounting intransigence in the British Army 1914-18," The British Accounting Review, Elsevier, vol. 53(2).
    13. Kalseth, Jorid & Halvorsen, Thomas & Kalseth, Birgitte & Sarheim Anthun, Kjartan & Peltola, Mikko & Kautiainen, Kirsi & Häkkinen, Unto & Medin, Emma & Lundgren, Jonatan & Rehnberg, Clas & Másdóttir, B, 2014. "Cross-country comparisons of health-care costs: The case of cancer treatment in the Nordic countries," Health Policy, Elsevier, vol. 115(2), pages 172-179.
    14. Allison Larg & John Moss, 2011. "Cost-of-Illness Studies," PharmacoEconomics, Springer, vol. 29(8), pages 653-671, August.
    15. Fernando Gracia & Mario Larreategui & Gaudencio Rodríguez & Aaron Benzadón & Michelle Ortiz & Divian Morales & Claudia Domínguez & Rosa Enith Carrillo & Carlos Valderrama & Luís Lizán & Blas Armién, 2018. "Costs of multiple sclerosis in Panama from societal, patient perspectives and health-related quality of life," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
    16. Foster, Nicola & Vassall, Anna & Cleary, Susan & Cunnama, Lucy & Churchyard, Gavin & Sinanovic, Edina, 2015. "The economic burden of TB diagnosis and treatment in South Africa," Social Science & Medicine, Elsevier, vol. 130(C), pages 42-50.
    17. Alemayehu Hailu & Bernt Lindtjørn & Wakgari Deressa & Taye Gari & Eskindir Loha & Bjarne Robberstad, 2017. "Economic burden of malaria and predictors of cost variability to rural households in south-central Ethiopia," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-16, October.
    18. Charmaine Shuyu Ng & Matthias Paul Han Sim Toh & Yu Ko & Joyce Yu-Chia Lee, 2015. "Direct Medical Cost of Type 2 Diabetes in Singapore," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-11, March.
    19. Stavroula Malla & Jill E. Hobbs & Eric K. Sogah, 2016. "Estimating the Potential Benefits of New Health Claims in Canada: The Case of Soluble Fiber and Soy Protein," Canadian Journal of Agricultural Economics/Revue canadienne d'agroeconomie, Canadian Agricultural Economics Society/Societe canadienne d'agroeconomie, vol. 64(2), pages 173-197, June.
    20. Elżbieta Antczak & Katarzyna M. Miszczyńska, 2021. "Causes of Sickness Absenteeism in Europe—Analysis from an Intercountry and Gender Perspective," IJERPH, MDPI, vol. 18(22), pages 1-22, November.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:hecrev:v:13:y:2023:i:1:d:10.1186_s13561-023-00459-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/13561 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.